RO 7033877Alternative Names: RO 7033877
Latest Information Update: 22 Apr 2016
At a glance
- Originator Roche
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 22 Apr 2016 Phase-I development is ongoing in USA and Netherlands
- 01 Jul 2014 Roche initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT02165332)
- 30 Jun 2014 Phase-I clinical trials in Healthy volunteers in Netherlands (IV) (NCT02156323)